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Pancreatic cancer (PCa) is resistant to cytotoxic therapies,
and the profound immune suppressive nature of this dis-
ease renders patients non-responsive to immunologic
therapies. Signaling downstream of IL-6 is important in
the genesis and progression of PCa. The IL-6/Jak2/STAT3
axis also mediates expansion of myeloid-derived suppres-
sor cells (MDSC). Indeed, the Jak2/STAT3 pathway is acti-
vated in human PCa specimens and cooperates with
activated Kras to drive initiation and progression of PCa in
murine models. We hypothesized that the Jak2 specific
inhibitor (BMS-911543; Bristol-Myers Squibb) would elicit
anti-tumor activity against PCa and decrease immune sup-
pressive features of the disease. Treatment of Kras wild
type (BxPC-3) and mutant (MIA Paca-2, Panc-1) human
PCa cell lines in vitro with BMS-911543 decreased viability
in a concentration-dependent manner. Similar inhibitory
effects of BMS-911543 were also observed upon stromal-
derived pancreatic stellate cells in vitro. These stromal
cells have been previously shown by our group to rely on
STAT3 signaling for survival, and secrete cytokines
involved in MDSC generation. BMS-911543 also had
immunomodulatory effects, as it significantly reduced IL-
6/GM-CSF driven MDSC differentiation (HLA-DRlo
CD11b+ CD33+) from healthy normal donor PBMC in
vitro. To evaluate in vivo activity of BMS-911543, we used
a genetically engineered PCa model with conditional
expression of mutant KrasG12D, tp53R270H, and Brca1
alleles in pancreatic cancer cells (Brca1-KPC mice). This
model accurately recapitulates many histologic and sys-
temic manifestations of PCa observed in patients, but at
an accelerated rate, which is advantageous for therapeutic
studies. By 5 weeks of age, Brca1-KPC mice have adeno-
carcinoma with 100% penetrance, pSTAT3 in the tumor
and stroma, high levels of MDSC, and increased plasma
IL-6. At 5-6 weeks of age, mice (n = 5/group) were imaged
by bioluminescent imaging (BLI) to confirm tumor burden
and were then treated with vehicle or BMS-911543 by oral
gavage daily for 14 days. Histologic analysis of pancreata
from treated mice showed fewer foci of adenocarcinoma
when compared to vehicle controls. Analysis of immune
biomarkers will focus on Jak2/STAT3 driven processes
such as the percentage of MDSC, T cell subset analysis
and inflammatory cytokines both systemically and in the
tumor microenvironment. These results provide rationale
for the design of future clinical trials that target Jak/STAT
signaling in patients with PCa.
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